{
    "Trade/Device Name(s)": [
        "LIAISON Lyme IgM",
        "LIAISON Lyme IgM Control Set",
        "LIAISON Lyme Total Antibody Plus"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K202573",
    "Predicate Device Reference 510(k) Number(s)": [
        "K900196",
        "K191240"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LSR",
        "QCH"
    ],
    "Summary Letter Date": "September 2, 2020",
    "Summary Letter Received Date": "September 4, 2020",
    "Submission Date": "May 05, 2020",
    "Regulation Number(s)": [
        "21 CFR 866.3830"
    ],
    "Regulation Name(s)": [
        "Treponema Pallidum Treponemal Test Reagents"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "immunology"
    ],
    "Analyte(s)": [
        "IgM antibodies to Borrelia burgdorferi"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Serum separator tube",
        "K2-EDTA tube",
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "LIAISON XL Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)"
    ],
    "Methodologies": [
        "Indirect chemiluminescence immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control Set"
    ],
    "Document Summary": "FDA 510(k) summary for LIAISON Lyme IgM CLIA assay and control set for qualitative detection of IgM antibodies to Borrelia burgdorferi in serum and plasma using the LIAISON XL Analyzer",
    "Indications for Use Summary": "Qualitative detection of IgM antibodies to Borrelia burgdorferi in human serum and plasma from patients with signs/symptoms or suspected Lyme disease; may be used as a confirmatory test in modified two-tier testing, and results should be interpreted alongside clinical data",
    "fda_folder": "Microbiology"
}